Alprazolam in the treatment of panic disorders.
Alprazolam in the treatment of panic disorders.
复制标题
阿普唑仑治疗恐慌症。
DOI：
10.1097/00004714-198602000-00004
复制
发表时间：
1986
影响因子：
2.9
通讯作者：
D. Klein
中科院分区：
文献类型：
--
作者：
M. Liebowitz;A. Fyer;J. Gorman;R. Campeas;A. Levin;S. Davies;D. Goetz;D. Klein
对惊恐障碍或伴有惊恐发作的广场恐惧症患者进行了阿普唑仑治疗的公开临床试验，以澄清先前研究未解决的某些问题。其中包括服用阿普唑仑后病情显着改善的患者比例；惊恐发作、预期性焦虑和恐惧性回避改善的相对时间过程；成功的阿普唑仑治疗是否可以通过乳酸钠输注改变恐慌的脆弱性；哪些因素可以预测恐慌患者对阿普唑仑的反应。 30 名符合 DSM-III 惊恐障碍或伴有惊恐发作的广场恐惧症标准的患者完成了为期 12 周的开放临床试验，其中 22 人被认为是有反应者。在反应者中，惊恐发作显示出快速改善，而预期焦虑和恐惧性回避的改善则变化较大。成功的阿普唑仑治疗似乎可以阻止乳酸脆弱性。治疗前汉密尔顿焦虑量表得分高与治疗反应差相关。数据表明，阿普唑仑是治疗惊恐障碍和伴有惊恐发作的广场恐惧症的有效药物，并通过直接阻止惊恐发作发挥作用。
An open clinical trial of alprazolam therapy of patients with panic disorder or agoraphobia with panic attacks was undertaken to clarify certain issues not resolved by previous studies. These included the proportion of patients who significantly improve with alprazolam; the relative time courses for improvement in panic attacks, anticipatory anxiety, and phobic avoidance; whether successful alprazolam treatment alters vulnerability to panic with sodium lactate infusion; and what factors predict response to alprazolam in panic patients. Thirty patients meeting DSM-III criteria for panic disorder or agoraphobia with panic attacks completed a 12-week open clinical trial, and 22 were considered responders. In responders, panic attacks showed rapid improvement, whereas improvement of anticipatory anxiety and phobic avoidance was more variable. Successful alprazolam therapy appeared to block lactate vulnerability. High pretreatment Hamilton Anxiety Scale scores were associated with poor treatment response. The data suggest that alprazolam is an effective treatment for panic disorder and agoraphobia with panic attacks, and acts by directly blocking panic attacks.